GAD-7 (Generalized Anxiety Disorder)
Calculate your GAD-7 anxiety screening score using the validated 7-item Generalized Anxiety Disorder questionnaire. Enter your symptom ratings to assess anxiety severity with interpretation and charts.
Over the past 2 weeks, how often have you been bothered by the following problems?
About This Calculator
The GAD-7 (Generalized Anxiety Disorder 7-item scale) calculator helps screen for and assess the severity of generalized anxiety disorder using the most widely validated and commonly used anxiety screening tool in clinical practice worldwide. Developed by Drs. Robert Spitzer, Kurt Kroenke, and colleagues in 2006, the GAD-7 is a brief 7-item self-administered questionnaire that measures the frequency and severity of core GAD symptoms over the past two weeks.
The GAD-7 has been validated across diverse healthcare settings including primary care, mental health specialties, and general population studies, with over 2,740 patients in the original validation study. It demonstrates excellent psychometric properties with a Cronbach alpha of 0.92 indicating outstanding internal consistency, and a sensitivity of 89% with specificity of 82% for generalized anxiety disorder at the standard cutoff score of 10. The questionnaire takes approximately 2-3 minutes to complete, making it highly efficient for routine screening in busy clinical environments.
Each of the 7 items is scored from 0 (not at all) to 3 (nearly every day), measuring how often the patient has been bothered by each symptom over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity: 0-4 indicates minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, and 15-21 severe anxiety. The GAD-7 is particularly sensitive for detecting GAD but also has reasonable sensitivity for other anxiety disorders including panic disorder, social anxiety disorder, and post-traumatic stress disorder.
Beyond initial screening, the GAD-7 is widely used to monitor treatment response over time. A clinically significant improvement is defined as a reduction of 4 or more points, and remission is typically defined as a score below 5. The scale is freely available in the public domain, has been translated into over 100 languages, and is recommended by major health organizations worldwide including the US Preventive Services Task Force and NICE guidelines.
Regional Notes
United States: The USPSTF recommends anxiety screening for all adults aged 18-64, including pregnant and postpartum individuals, using validated instruments like the GAD-7. The GAD-2 (first 2 items) is sometimes used as an ultra-brief initial screener, with the full GAD-7 administered if the GAD-2 is positive. Medicare and most insurance plans cover annual mental health screening. Crisis resources: National Suicide Prevention Lifeline 988.
United Kingdom: NICE guidelines (CG113) recommend the GAD-7 for initial assessment and monitoring of GAD severity in primary care and IAPT (Improving Access to Psychological Therapies) services. Treatment follows a stepped-care model with low-intensity interventions for mild cases and CBT plus pharmacotherapy for moderate to severe cases. Crisis resources: Samaritans 116 123.
India: The National Mental Health Programme (NMHP) and District Mental Health Programme (DMHP) increasingly incorporate screening tools like the GAD-7 at the primary care level. Hindi and other regional language translations are available. Access to mental health specialists remains limited, with fewer than 0.75 psychiatrists per 100,000 population. Crisis resources: iCall 9152987821, Vandrevala Foundation 1860-2662-345.
Frequently Asked Questions
What is the GAD-7 and what does it measure?
The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a validated self-administered screening tool developed by Drs. Robert Spitzer, Kurt Kroenke, and colleagues in 2006. It measures the severity of generalized anxiety disorder symptoms over the past two weeks. The seven items assess: feeling nervous/anxious/on edge, inability to stop worrying, excessive worry about different things, trouble relaxing, restlessness, irritability, and fear of something awful happening. Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score range of 0 to 21.
How is the GAD-7 score interpreted for anxiety severity?
The GAD-7 total score is interpreted as follows: 0-4 indicates minimal anxiety (monitor, no treatment typically needed). 5-9 indicates mild anxiety (clinical judgment needed based on functional impairment). 10-14 indicates moderate anxiety (active treatment warranted with psychotherapy or pharmacotherapy). 15-21 indicates severe anxiety (pharmacotherapy and psychotherapy strongly indicated, consider psychiatric referral). At a cutoff score of 10, the GAD-7 has a sensitivity of 89% and specificity of 82% for diagnosing generalized anxiety disorder.
Is a positive GAD-7 score sufficient for diagnosing generalized anxiety disorder?
No. The GAD-7 is a screening tool, not a diagnostic instrument. A definitive diagnosis of generalized anxiety disorder requires a clinical interview that establishes excessive worry occurring more days than not for at least six months, difficulty controlling the worry, and associated symptoms such as restlessness, fatigue, concentration difficulties, irritability, muscle tension, and sleep disturbance. The GAD-7 helps screen for and quantify anxiety severity but should not replace a comprehensive evaluation by a mental health professional.
What should I do if I scored high on the GAD-7?
If you scored in the moderate to severe range (10+), consult a healthcare professional for a comprehensive evaluation. Evidence-based treatments for GAD include cognitive behavioral therapy (CBT), which is considered the first-line psychotherapeutic approach, and pharmacotherapy with SSRIs (sertraline, escitalopram, paroxetine) or SNRIs (venlafaxine, duloxetine). If you are experiencing thoughts of self-harm, contact a crisis helpline immediately: National Suicide Prevention Lifeline (US): 988, Samaritans (UK): 116 123, iCall (India): 9152987821.
What treatments are effective for generalized anxiety disorder?
First-line treatment for GAD includes cognitive behavioral therapy (CBT), which helps patients identify and challenge anxiety-provoking thought patterns and gradually face feared situations. Pharmacotherapy options include SSRIs (sertraline, escitalopram, paroxetine) and SNRIs (venlafaxine, duloxetine) as first-line medications. Benzodiazepines such as alprazolam (Xanax) and clonazepam (Rivotril) may be used for short-term symptom relief but carry risk of dependence. Lifestyle modifications including regular exercise, mindfulness meditation, caffeine reduction, and improved sleep hygiene are also beneficial adjuncts.
Who developed the GAD-7 and how is it validated?
The GAD-7 was developed by Drs. Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, and Bernd Löwe in 2006 as part of the Patient Health Questionnaire (PHQ) family. It was validated in a study of 2,740 patients across 15 primary care sites. The GAD-7 demonstrates excellent internal consistency (Cronbach alpha of 0.92) and good test-retest reliability (intraclass correlation of 0.83). At the optimal cutoff score of 10, it has a sensitivity of 89% and specificity of 82% for generalized anxiety disorder.
Can the GAD-7 be used to monitor treatment response over time?
Yes. The GAD-7 is widely used to monitor treatment response in patients undergoing treatment for anxiety disorders. A clinically meaningful improvement is typically defined as a reduction of 4 or more points from baseline. The scale can be administered at each follow-up visit to track symptom changes and guide treatment decisions. Remission is often defined as a GAD-7 score below 5. The scale is sensitive to change and correlates well with clinician-rated anxiety severity measures.
What are the differences in anxiety screening guidelines between the US, UK, and India?
In the US, the USPSTF recommends anxiety screening for adults aged 18-64, including pregnant and postpartum individuals, using validated instruments like the GAD-7. In the UK, NICE guidelines recommend the GAD-7 for initial assessment and monitoring of GAD severity in primary care and IAPT (Improving Access to Psychological Therapies) services. In India, the National Mental Health Programme (NMHP) increasingly incorporates screening tools like the GAD-7, though awareness and access to mental health services remain limited, especially in rural areas.